Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study by Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi

Get full text

Off-label transcatheter aortic valve-in-valve implantation in severe bioprosthetic aortic valve dysfunction after bioprosthetic Bentall operation: a scoping review, case study and proposed approach by Nicholas Wen-Sheng Chew, Rodney Yu-Hang Soh, Gwyneth Kong, Yinghao Lim, Ivandito Kuntjoro

Get full text

An Open-Label Comparative Study of the Impact of Two Types of Electrical Stimulation (Direct Current Neuromuscular Electrical Stimulation and Transcutaneous Electrical Stimulation) on Physical Therapy Treatment of Diabetic Peripheral Neuropathy by Dimitrios Kostopoulos, Konstantine Rizopoulos, Joe McGilvrey, Jennifer Hauskey, Jeff Courcier, Kay Connor-Israel, Harry Koster, Ramona von Leden

Get full text

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer by Rahul Aggarwal, Joshi J. Alumkal, Russell Z. Szmulewitz, Celestia S. Higano, Alan H. Bryce, Angela Lopez-Gitlitz, Sharon A. McCarthy, Branko Miladinovic, Kelly McQuarrie, Shibu Thomas, Ke Zhang, Eric J. Small

“…Patients with BCR PC after primary definitive therapy and prostate-specific antigen (PSA) doubling time ≤12 months were randomized to open-label apalutamide (240 mg/d) alone, apalutamide plus ADT, or ADT alone (1 : 1:1 ratio) for 12 months followed by a 12-month observation period (NCT01790126). …”
Get full text

Perioperative and mid-term results of trans-graft embolization of the hypogastric artery for treatment of type II endoleaks after endovascular aortic repair with off-label use of re-entry catheters by Filippo Griselli, MD, Alessia D’Andrea, MD, Sandro Lepidi, MD, Beatrice Grando, MD, Giovanni Badalamenti, MD, Mario D’Oria, MD

“…Herein, we present the perioperative and mid-term results of one of our endovascular aortic repair cases with type II endoleak from the hypogastric artery, whose ostium was covered by the prior stent graft limbs and that were successfully treated with a novel technique employing re-entry catheters in an off-label fashion. This technique may represent a valid alternative solution when conventional access between artery and prosthesis is laborious or impossible to achieve.…”
Get full text

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy) by Yingyi Li, Yuqin Cao, Xipeng Wang, Chengqiang Li, Liqin Zhao, Hecheng Li

“…Methods The AEGIS study is a prospective, open-labeled, single-arm, phase II clinical trial. A total of 26 patients with AEG will be enrolled. …”
Get full text

Prospective Multicenter Open-Label One-Arm Trial Investigating a Pumpkin Seed, Isoflavonoids, and Cranberry Mix in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: A Pilot Study by Elie Nemr, Elie El Helou, Georges Mjaess, Albert Semaan, Josselin Abi Chebel

Get full text

Effectiveness of Cognitive Behavioral Therapy Provided Through a Web Application for Subthreshold Depression, Subthreshold Insomnia, and Subthreshold Panic: Open-Labeled 6-Arm Randomized Clinical Trial Pilot Study by Kayoko Taguchi, Mirai Miyoshi, Yoichi Seki, Shiori Baba, Eiji Shimizu

Get full text

Efficacy of Nonpreserved Sodium Hyaluronate Artificial Tears in Dry Eye Disease Patients Treated with Prostaglandin Analogs for Primary Open-Angle Glaucoma: A Prospective, Nonrandomized, Open-Label Pilot Study by Giulia Coco, Danilo Iannetta, Igino Febbraro, Ester Elmo, Gianluca Manni

“…In this prospective, nonrandomized, open-label pilot study, we evaluated the efficacy of a 0.15% hyaluronic acid (HA) nonpreserved ophthalmic formulation in decreasing DED symptoms in patients with open-angle glaucoma treated with prostaglandin analogs. …”
Get full text

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol by Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present

“…The Drug Rediscovery in IMIDs (DRIMID) consortium aims to conduct a prospective pilot basket trial to investigate the effects of filgotinib, a JAK1 preferential inhibitor approved for ulcerative colitis and rheumatoid arthritis, on disease activity, quality of life and safety in patients with refractory BD, IIM and IgG4-RD.Methods and analysis In this investigator-initiated, multicentre, open-label phase 2 study, up to 60 patients with rare IMIDs will be enrolled for a 26-week treatment period with filgotinib 200 mg once daily. …”
Get full text

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial by Jorge E. Cortes, Gail J. Roboz, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, P. Brent Ferrell, Jay Yang, Eunice S. Wang, William G. Blum, Alice Mims, Hua Tian, Aaron Sheppard, Stéphane de Botton, Pau Montesinos, Antonio Curti, Justin M. Watts, the Olutasidenib Combination Therapy Study Group

Get full text

Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT) by Kazuomi Kario, Tomohiro Katsuya, Tatsuo Shimosawa, Takashi Taguchi, Ayumi Tanabe, Mitsuru Ohishi, the ESCORT‐HT investigators

“…The ESCORT‐HT study is a multicenter, randomized, controlled, open‐label, parallel‐group study with a 4‐week run‐in period and 12‐week treatment period. …”
Get full text

Do cognitive bias and heuristics influence improvement in knee pain in patients with knee osteoarthritis treated with open label placebo? The CHIPS study - An exploratory study using questionnaire and group concept mapping by Tommy Kok Annfeldt, Elisabeth Ginnerup-Nielsen, Eva Elisabeth Wæhrens, Lene Vase, Lars Erik Kristensen, Tanja Schjødt Jørgensen

Subjects: “…Open-label placebo…”
Get full text

Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension by Sofia Ramiro, Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Lianne S Gensler, Helena Marzo-Ortega, Natasha de Peyrecave, Victoria Navarro-Compán, Tetsuya Tomita, Carmen Fleurinck, Ute Massow, Thomas Vaux

“…Objective Assess long-term safety, tolerability and efficacy of bimekizumab in ankylosing spondylitis (radiographic axial spondyloarthritis (r-axSpA)).Methods Patients with active r-axSpA completing the dose-ranging 48-week randomised controlled trial could enrol in the open-label extension, where patients received bimekizumab 160 mg every 4 weeks. …”
Get full text

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

“…This study is designed to further validate the efficacy and safety of the combination therapy of low-dose lenvatinib and PD-1 inhibitor toripalimab in patients with recurrent PROC.Study Design and Methods: The study is designed as a multicenter, open-label, single-arm, prospective phase II study. Patients with recurrent epithelial ovarian cancer who have disease progression either during or within 6 months after completion of platinum-based therapy will be included. …”
Get full text

A prospective, randomized, single-center, two-arm, open-label study to evaluate the efficacy of biotherapi®, a two-strain bacillus probiotic blend, as an adjunctive therapy in the treatment of rheumatoid arthritis by Arindam Nandy Roy, Yarram Ashok Kumar, Syeda Sana Fatima

“…Methods: In this prospective, randomized, single-center, two-arm, open-label study, patients were randomized (1:1) to receive twice-daily adjunctive Biotherapi® (n = 125) or standard of care alone (n = 125) for 12 weeks. …”
Get full text

S³DR-Det: A Rotating Target Detection Model for High Aspect Ratio Shipwreck Targets in Side-Scan Sonar Images by Quanhong Ma, Shaohua Jin, Gang Bian, Yang Cui, Guoqing Liu, Yihan Wang

Subjects: Get full text

Density functional theory calculation for understanding the roles of biochar in immobilizing exchangeable Al3 + and enhancing soil quality in acidic soils by Debo He, Xinyi Liu, Dongni Hu, Ping Lei, Jinbo Zhang, Zhixin Dong, Bo Zhu

Subjects: Get full text

A Stitch in Time by Brigid O’Farrell

Subjects: Get full text

SaliencyMix+: Noise-Minimized Image Mixing Method With Saliency Map in Data Augmentation by Hajeong Lee, Zhixiong Jin, Jiyoung Woo, Byeongjoon Noh

Subjects: Get full text